To read this article, head to PDA Journal of Pharmaceutical Science Technology by clicking this link.

Abstract

Maintaining microbial control in pharmaceutical manufacturing environments is a cornerstone of Good Manufacturing Practices (GMP). This comprehensive review outlines the development, validation, and implementation of robust cleaning and disinfection programs for pharmaceutical facilities, including cleanrooms, Restricted Access Barrier Systems (RABS), and isolators. The article integrates regulatory expectations from U.S. FDA (21 CFR 211), EU GMP Annex 1, and industry guidance documents such as USP <1072>, PDA TR70, and IEST RP 18.5, emphasizing the importance of both laboratory-based disinfectant efficacy studies and in situ field trials. Key topics include the selection and rotation of disinfectants and sporicidal agents, validation methodologies, environmental monitoring strategies, and the role of Vaporized Hydrogen Peroxide (VHP) in bio-decontamination. Case studies and data-driven insights illustrate best practices for ensuring contamination control, including equipment cleaning validation and requalification protocols. The article advocates for a sound approach to validate both manual and automated disinfection technologies, offering a forward-looking perspective on contamination control in modern pharmaceutical manufacturing.